Trade Ocugen, Inc. - OCGN CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Trading Conditions
| Spread | 0.05 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.0064% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | -0.0059% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 20% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Key Stats
| Prev. Close* | 1.43 |
| Open* | 1.43 |
| 1-Year Change* | -77.59% |
| Day's Range* | 1.38 - 1.38 |
| 52 wk Range | 1.48-7.55 |
| Average Volume (10 days) | 4.8687 |
| Average Volume (3 months) | 106.018 |
| Market Cap | 339.275 |
| P/E Ratio | N/A |
| Shares Outstanding | 218887000 |
| Revenue | N/A |
| EPS | -0.35219 |
| Dividend (Yield %) | N/A |
| Beta | 4.03869 |
| Next Earnings Date | Feb 23, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Nov 30, 2022 | 1.42 | 0.00 | 0.00% | 1.42 | 1.43 | 1.40 |
| Nov 29, 2022 | 1.43 | 0.00 | 0.00% | 1.43 | 1.47 | 1.40 |
| Nov 28, 2022 | 1.43 | -0.04 | -2.72% | 1.47 | 1.51 | 1.42 |
| Nov 25, 2022 | 1.48 | -0.05 | -3.27% | 1.53 | 1.53 | 1.48 |
| Nov 23, 2022 | 1.50 | 0.00 | 0.00% | 1.50 | 1.56 | 1.48 |
| Nov 22, 2022 | 1.51 | -0.02 | -1.31% | 1.53 | 1.57 | 1.48 |
| Nov 21, 2022 | 1.54 | -0.03 | -1.91% | 1.57 | 1.59 | 1.51 |
| Nov 18, 2022 | 1.57 | 0.03 | 1.95% | 1.54 | 1.63 | 1.54 |
| Nov 17, 2022 | 1.55 | -0.07 | -4.32% | 1.62 | 1.63 | 1.54 |
| Nov 16, 2022 | 1.62 | -0.03 | -1.82% | 1.65 | 1.72 | 1.60 |
| Nov 15, 2022 | 1.66 | -0.03 | -1.78% | 1.69 | 1.76 | 1.65 |
| Nov 14, 2022 | 1.69 | -0.06 | -3.43% | 1.75 | 1.77 | 1.66 |
| Nov 11, 2022 | 1.74 | 0.11 | 6.75% | 1.63 | 1.80 | 1.61 |
| Nov 10, 2022 | 1.64 | 0.10 | 6.49% | 1.54 | 1.70 | 1.45 |
| Nov 9, 2022 | 1.45 | -0.13 | -8.23% | 1.58 | 1.60 | 1.44 |
| Nov 8, 2022 | 1.59 | 0.09 | 6.00% | 1.50 | 1.66 | 1.49 |
| Nov 7, 2022 | 1.51 | -0.05 | -3.21% | 1.56 | 1.61 | 1.48 |
| Nov 4, 2022 | 1.58 | 0.04 | 2.60% | 1.54 | 1.62 | 1.54 |
| Nov 3, 2022 | 1.54 | -0.04 | -2.53% | 1.58 | 1.64 | 1.53 |
| Nov 2, 2022 | 1.59 | -0.08 | -4.79% | 1.67 | 1.70 | 1.56 |
Ocugen, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
- Annual
- Quarterly
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0.04262 | 0 |
| Revenue | 0 | 0 | 0 | 0.04262 | 0 | |
| Total Operating Expense | 30.307 | 24.95 | 28.568 | 14.5038 | 21.3273 | 57.628 |
| Selling/General/Admin. Expenses, Total | 8.53 | 9.384 | 10.204 | 6.0771 | 7.97405 | 22.92 |
| Research & Development | 21.577 | 15.566 | 15.634 | 8.08552 | 13.3533 | 35.108 |
| Unusual Expense (Income) | 0.2 | 0 | 2.73 | 0.34114 | 0 | -0.4 |
| Operating Income | -30.307 | -24.95 | -28.568 | -14.5038 | -21.2847 | -57.628 |
| Interest Income (Expense), Net Non-Operating | 14.347 | -1.348 | 20.031 | -4.95401 | -0.71989 | -0.079 |
| Other, Net | -0.248 | -0.116 | -0.106 | -0.78487 | 0.18266 | -0.71 |
| Net Income Before Taxes | -16.208 | -26.414 | -8.643 | -20.2426 | -21.822 | -58.417 |
| Net Income After Taxes | -16.208 | -26.414 | -8.643 | -20.2426 | -21.822 | -58.365 |
| Net Income Before Extra. Items | -16.208 | -26.414 | -8.643 | -20.2426 | -21.822 | -58.365 |
| Net Income | -16.208 | -26.414 | -8.643 | -20.2426 | -21.822 | -58.365 |
| Total Adjustments to Net Income | 2.345 | 3.915 | 0.121 | -12.5463 | 0 | |
| Income Available to Common Excl. Extra. Items | -13.863 | -22.499 | -8.522 | -20.2426 | -34.3683 | -58.365 |
| Income Available to Common Incl. Extra. Items | -13.863 | -22.499 | -8.522 | -20.2426 | -34.3683 | -58.365 |
| Diluted Net Income | -13.863 | -22.499 | -8.522 | -20.2426 | -34.3683 | -58.365 |
| Diluted Weighted Average Shares | 0.23766 | 0.37791 | 0.60676 | 13.8938 | 112.236 | 195.013 |
| Diluted EPS Excluding Extraordinary Items | -58.3304 | -59.536 | -14.045 | -1.45695 | -0.30621 | -0.29929 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | ||||
| Diluted Normalized EPS | -57.4889 | -59.536 | -9.54575 | -1.4324 | -0.30621 | -0.30062 |
| Total Extraordinary Items | 0 |
| Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 7.057 | 25.61 | 10.389 | 14.572 | 18.034 |
| Selling/General/Admin. Expenses, Total | 4.185 | 6.757 | 4.508 | 7.47 | 10.119 |
| Research & Development | 2.872 | 18.853 | 6.281 | 7.102 | 7.915 |
| Operating Income | -7.057 | -25.61 | -10.389 | -14.572 | -18.034 |
| Interest Income (Expense), Net Non-Operating | -0.02 | -0.01 | -0.014 | -0.035 | |
| Net Income Before Taxes | -7.077 | -25.952 | -10.807 | -14.581 | -18.019 |
| Net Income After Taxes | -7.077 | -25.952 | -10.755 | -14.581 | -18.019 |
| Net Income Before Extra. Items | -7.077 | -25.952 | -10.755 | -14.581 | -18.019 |
| Net Income | -7.077 | -25.952 | -10.755 | -14.581 | -18.019 |
| Income Available to Common Excl. Extra. Items | -7.077 | -25.952 | -10.755 | -14.581 | -18.019 |
| Income Available to Common Incl. Extra. Items | -7.077 | -25.952 | -10.755 | -14.581 | -18.019 |
| Diluted Net Income | -7.077 | -25.952 | -10.755 | -14.581 | -18.019 |
| Diluted Weighted Average Shares | 186.298 | 195.572 | 198.791 | 199.254 | 205.693 |
| Diluted EPS Excluding Extraordinary Items | -0.03799 | -0.1327 | -0.0541 | -0.07318 | -0.0876 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.03799 | -0.1327 | -0.05541 | -0.07318 | -0.0876 |
| Revenue | 0 | 0 | 0 | ||
| Other, Net | -0.332 | -0.404 | 0.026 | 0.015 | |
| Total Adjustments to Net Income | 0 | 0 | 0 | ||
| Unusual Expense (Income) | -0.4 | 0 |
- Annual
- Quarterly
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Total Current Assets | 32.081 | 8.175 | 16.4 | 15.7662 | 25.8777 | 102.646 |
| Cash and Short Term Investments | 31.908 | 7.981 | 15.542 | 7.44405 | 24.0393 | 94.958 |
| Cash & Equivalents | 31.908 | 7.081 | 15.542 | 7.44405 | 24.0393 | 94.958 |
| Prepaid Expenses | 0.173 | 0.194 | 0.686 | 1.32217 | 1.83836 | 2.7 |
| Total Assets | 36.078 | 11.035 | 17.428 | 16.8074 | 27.3764 | 105.761 |
| Property/Plant/Equipment, Total - Net | 3.86 | 2.723 | 0.141 | 0.22246 | 1.06662 | 2.751 |
| Intangibles, Net | 0 | |||||
| Other Long Term Assets, Total | 0.137 | 0.137 | 0.887 | 0.81876 | 0.43205 | 0.364 |
| Total Current Liabilities | 5.171 | 3.805 | 2.873 | 4.54396 | 3.61355 | 7 |
| Accounts Payable | 1.948 | 0.776 | 1.59 | 1.89561 | 0.39503 | 2.312 |
| Accrued Expenses | 2.097 | 2.705 | 1 | 2.44236 | 2.97464 | 4.688 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0.583 | 0.178 | 0 | 0 | 0.23412 | 0 |
| Other Current Liabilities, Total | 0.543 | 0.146 | 0.283 | 0.20599 | 0.00976 | |
| Total Liabilities | 22.511 | 22.303 | 17.886 | 5.78904 | 5.82591 | 9.943 |
| Total Long Term Debt | 0.178 | 0 | 0 | 1.07212 | 1.82304 | 1.712 |
| Long Term Debt | 0.178 | 0 | 1.07212 | 1.82304 | 1.712 | |
| Other Liabilities, Total | 17.162 | 18.498 | 15.013 | 0.17295 | 0.38932 | 1.231 |
| Total Equity | 13.567 | -11.268 | -0.458 | 11.0184 | 21.5504 | 95.818 |
| Common Stock | 0.159 | 0.159 | 0.513 | 0.52747 | 1.84133 | 1.995 |
| Additional Paid-In Capital | 195.181 | 196.76 | 215.859 | 62.0186 | 93.0587 | 225.537 |
| Retained Earnings (Accumulated Deficit) | -181.773 | -208.187 | -216.83 | -51.4798 | -73.3018 | -131.667 |
| Total Liabilities & Shareholders’ Equity | 36.078 | 11.035 | 17.428 | 16.8074 | 27.3764 | 105.761 |
| Total Common Shares Outstanding | 0.3442 | 0.4096 | 1.03376 | 52.6252 | 184.012 | 199.381 |
| Short Term Investments | 0.9 | 0 | ||||
| Redeemable Preferred Stock | 0 | 0 | 0 | 0.001 | ||
| Other Equity, Total | 0 | 0 | ||||
| Other Current Assets, Total | 0.172 | 7 | 0 | 4.988 | ||
| Property/Plant/Equipment, Total - Gross | 10.427 | 1.29231 | 3.125 | |||
| Accumulated Depreciation, Total | -10.286 | -0.2257 | -0.374 | |||
| Treasury Stock - Common | -0.04786 | -0.04786 | -0.048 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 51.356 | 121.626 | 113.45 | 102.646 | 138.027 |
| Cash and Short Term Investments | 44.792 | 115.642 | 107.349 | 94.958 | 129.771 |
| Cash & Equivalents | 44.792 | 115.642 | 107.349 | 94.958 | 129.771 |
| Prepaid Expenses | 1.576 | 0.996 | 1.113 | 2.7 | 8.256 |
| Other Current Assets, Total | 4.988 | 4.988 | 4.988 | 4.988 | |
| Total Assets | 53.847 | 124.251 | 116.312 | 105.761 | 141.727 |
| Property/Plant/Equipment, Total - Net | 0.762 | 0.944 | 1.052 | 2.751 | 3.345 |
| Property/Plant/Equipment, Total - Gross | 0.988 | 1.219 | 1.386 | 3.125 | 3.786 |
| Accumulated Depreciation, Total | -0.226 | -0.275 | -0.334 | -0.374 | -0.441 |
| Other Long Term Assets, Total | 1.729 | 1.681 | 1.81 | 0.364 | 0.355 |
| Total Current Liabilities | 4.281 | 4.84 | 6.229 | 7 | 7.687 |
| Accounts Payable | 1.04 | 0.802 | 2.095 | 2.312 | 3.896 |
| Accrued Expenses | 2.867 | 4.038 | 4.134 | 4.688 | 3.791 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0.374 | 0 | 0 | 0 | |
| Total Liabilities | 7.358 | 7.842 | 9.202 | 9.943 | 10.598 |
| Total Long Term Debt | 1.702 | 1.674 | 1.693 | 1.712 | 1.731 |
| Long Term Debt | 1.702 | 1.674 | 1.693 | 1.712 | 1.731 |
| Other Liabilities, Total | 1.375 | 1.328 | 1.28 | 1.231 | 1.18 |
| Total Equity | 46.489 | 116.409 | 107.11 | 95.818 | 131.129 |
| Common Stock | 1.883 | 1.988 | 1.99 | 1.995 | 2.158 |
| Additional Paid-In Capital | 125.032 | 220.799 | 222.253 | 225.537 | 278.704 |
| Retained Earnings (Accumulated Deficit) | -80.379 | -106.331 | -117.086 | -131.667 | -149.686 |
| Treasury Stock - Common | -0.048 | -0.048 | -0.048 | -0.048 | -0.048 |
| Other Equity, Total | 0.001 | ||||
| Total Liabilities & Shareholders’ Equity | 53.847 | 124.251 | 116.312 | 105.761 | 141.727 |
| Total Common Shares Outstanding | 188.156 | 198.695 | 198.928 | 199.381 | 215.631 |
| Redeemable Preferred Stock | 0.001 | 0.001 | 0.001 | 0.001 |
- Annual
- Quarterly
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Net income/Starting Line | -16.208 | -26.414 | -8.643 | -20.2426 | -21.822 | -58.365 |
| Cash From Operating Activities | -25.736 | -23.02 | -15.777 | -16.8933 | -14.7087 | -47.941 |
| Cash From Operating Activities | 1.673 | 1.534 | 0.45 | 0.06061 | 0.10211 | 0.229 |
| Non-Cash Items | -13.192 | 2.566 | -14.779 | 6.40129 | 8.2213 | 7.757 |
| Cash Taxes Paid | 0.257 | 0.197 | 0.105 | 0.052 | ||
| Cash Interest Paid | 0.066 | 0.03 | 0.001 | |||
| Changes in Working Capital | 1.991 | -0.706 | 7.195 | -3.11255 | -1.21018 | 2.438 |
| Cash From Investing Activities | -0.32 | -1.23 | -1.113 | -2.35672 | -0.30683 | -1.816 |
| Capital Expenditures | -0.32 | -0.276 | -2.013 | -0.02945 | -0.30683 | -1.066 |
| Cash From Financing Activities | 27.049 | -0.577 | 25.351 | 25.0665 | 31.611 | 120.676 |
| Financing Cash Flow Items | -0.583 | -0.583 | -0.178 | -0.17293 | -1.48355 | -8.525 |
| Issuance (Retirement) of Stock, Net | 27.632 | 0.006 | 25.529 | 23.7294 | 37.822 | 129.211 |
| Net Change in Cash | 0.993 | -24.827 | 8.461 | 5.81646 | 16.5955 | 70.919 |
| Other Investing Cash Flow Items, Total | -0.954 | 0.9 | -2.32727 | 0 | -0.75 | |
| Issuance (Retirement) of Debt, Net | 1.51 | -4.72744 | -0.01 | |||
| Foreign Exchange Effects | 0 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -7.077 | -33.029 | -43.784 | -58.365 | -18.019 |
| Cash From Operating Activities | -5.283 | -27.084 | -35.137 | -47.941 | -15.066 |
| Cash From Operating Activities | 0.044 | 0.093 | 0.151 | 0.229 | 0.076 |
| Non-Cash Items | 0.921 | 3.434 | 4.869 | 7.757 | 3.497 |
| Changes in Working Capital | 0.829 | 2.418 | 3.627 | 2.438 | -0.62 |
| Cash From Investing Activities | -0.261 | -1.274 | -1.624 | -1.816 | -0.223 |
| Capital Expenditures | -0.261 | -0.524 | -0.874 | -1.066 | -0.223 |
| Cash From Financing Activities | 26.297 | 119.961 | 120.071 | 120.676 | 50.102 |
| Financing Cash Flow Items | -1.822 | -8.525 | -8.525 | -8.525 | -0.075 |
| Issuance (Retirement) of Stock, Net | 28.125 | 128.496 | 128.606 | 129.211 | 50.177 |
| Issuance (Retirement) of Debt, Net | -0.006 | -0.01 | -0.01 | -0.01 | 0 |
| Net Change in Cash | 20.753 | 91.603 | 83.31 | 70.919 | 34.813 |
| Other Investing Cash Flow Items, Total | -0.75 | -0.75 | -0.75 | ||
| Cash Taxes Paid | 0.052 | 0.052 |
Why choose Capital.com? Our numbers speak for themselves.
Capital.com Group 475000+
Traders
71000+
Active clients monthly
$51000000+
Monthly investing volume
$30000000+
Try now Withdrawn each month
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Trade commission
0
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
Leverage
20:1
- 20
- 100
- 500
- 1000
- 10000
Investment
Trade size (Leverage x Investement):
Open
Close
Short Long
Ocugen, Inc. Company profile
Ocugen (OCGN) is a biopharmaceutical company focusing on discovering, developing, and commercialising gene therapies to cure blindness illnesses and creating a Covid-19 vaccine.
Founded in 2006, Ocugen became a public company in 2014. The company’s shares are traded on the Nasdaq under the symbol OCGN.
Projects in the pipeline are Covid-19 vaccines, a Modifier Gene Therapy Platform and Novel Biologic Therapies for Retinal Diseases.
For the Covid-19 vaccine, the company, in collaboration Bharat Biotech, was developing, manufacturing and commercialising COVAXIN for the prevention of the disease for US and Canada markets. COVAXIN is a whole-virion inactivated Covid-19 vaccine candidate and is formulated with the inactivated SARS-CoV-2 virus.
The Modifier Gene Therapy Platform is designed for retinal diseases, including retinitis pigmentosa (RP), leber congenital amaurosis (LCA) and dry age-related macular degeneration (AMD). The technology is licensed from the Schepens Eye Research Institute of Massachusetts Eye and Ear (Harvard Medical School).
The company is developing OCU200, a biologic product candidate for the treatment of severe vision-threatening diseases such as diabetic macular edema (DME), diabetic retinopathy (DR), and wet age-related macular degeneration (Wet-AMD).
Patients affected by these diseases have common symptoms, such as blurry vision and increasing visual loss as the condition develops.
Another technology in the pipeline is OCU400, the company’s first product candidate developed with its Modifier Gene Therapy Platform.
Ocugen is headquartered in Malvern, Pennsylvania.
| Industry: | Biotechnology & Medical Research (NEC) |
11 Great Valley Parkway
MALVERN
PENNSYLVANIA 19355
US
Income Statement
News
Cardano co-founder Charles Hoskinson: ‘Crypto is never going to zero – we are a religion at this point’
Hoskinson also said: “Crypto is the only solution where everyone is truly, truly equal”
14:57, 30 November 2022
H&M and Primark: Fashion on a budget and why HM is downsizing and ABF is expanding
Budget clothing brands emerge as winners as inflation bites this holiday season
14:38, 30 November 2022
USD/JPY outlook: Traders look ahead to Powell speech, and inflation and jobs data
USD/JPY sideways consolidation is underway as traders await key events.
13:47, 30 November 2022
Can EUR/USD maintain rally as recession fears begin to overshadow inflation?
Stable year-over-year inflation is a positive sign – even when the numbers are still this bad.
12:41, 30 November 2022
BYD eyes push into North America: EV maker to launch Mexico sales next year
BYD continues on a global expansion, beats Tesla’s growth rate
12:16, 30 November 2022People also watch
Still looking for a broker you can trust?
Join the 475.000+ traders worldwide that chose to trade with Capital.com